Sclerosis multiplex (SM): vizsgálatok itt: Belgium
19 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
- Where
- Anderlecht, Gent, Pelt, Steenokkerzeel
- Életkor
- 18 év to 60 év
- People
- 705 worldwide
- Run by
- Zenas BioPharma (USA), LLC
See details and how to joinNCT07067463 · EU 2025-524316-11-00 - 3. fázisTaking peopleA Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
- Where
- Eeklo, Pelt, Sint-Lambrechts-Woluwe
- Életkor
- 18 év to 60 év
- People
- 990 worldwide
- Run by
- Zenas BioPharma (USA), LLC
See details and how to joinNCT07299019 · EU 2025-524322-18-00 - No phaseNot yet taking people in BelgiumThe Role of the FCRL5 Protein in the Pathophysiology of Multiple Sclerosis and Response to Treatment
- Where
- Brussels
- Életkor
- 18 év to 80 év
- People
- 90
- Run by
- Université Catholique de Louvain
See details and how to joinNCT07788573 - 3. fázisTaking peopleEfficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis
- Where
- Gent, Pelt
- Életkor
- 18 év to 64 év
- People
- 386 worldwide
- Run by
- Sanofi-Aventis Recherche & Developpement
See details and how to join2023-504358-36-00 · EU 2023-504358-36-00 - 3. fázisTaking peopleEfficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
- Where
- Brugge, Pelt
- Életkor
- 40 év to 70 év
- People
- 400 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06846281 · EU 2023-509275-17-00 - 3. fázisTaking peopleA Randomized, Double-blind, Study to Demonstrate Pharmacokinetic Similarity, and Evaluate Safety, Immunogenicity, Pharmacodynamics and Clinical Effects between ABP 692 and Ocrevus® (Ocrelizumab) in Subjects with Relapsing-remitting Multiple Sclerosis
- Where
- Roeselare
- Életkor
- 18 év to 64 év
- People
- 125 worldwide
- Run by
- Amgen Inc.
See details and how to join2024-512914-16-00 · EU 2024-512914-16-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
- Where
- Bonheiden, Brussels, Leuven, Roeselare
- Életkor
- 18 év to 65 év
- People
- 1275 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07225504 - 3. fázisTaking peopleNon-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
- Where
- Brugge, Gent, Kortrijk, Pelt, Sint-Lambrechts-Woluwe, Steenokkerzeel
- Életkor
- 18 év to 60 év
- People
- 160 worldwide
- Run by
- Sanofi
See details and how to joinNCT07325292 · EU 2026-525688-41-00 - No phaseTaking peopleAt Home Use of Stimulation Suits for Managing MS Symptoms
- Where
- Steenokkerzeel
- Életkor
- 18 év and over
- People
- 70 worldwide
- Run by
- Daphne Kos
See details and how to joinNCT07202195 - 3. fázisTaking peopleEfficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis
- Where
- Gent
- Életkor
- Up to 17 év
- People
- 64 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2024-511686-11-00 · EU 2024-511686-11-00 - 2. fázisTaking peopleA Phase 2 Study of Obexelimab in Patients with Relapsing Multiple Sclerosis
- Where
- Pelt
- Életkor
- 18 év to 64 év
- People
- 93 worldwide
- Run by
- Zenas Biopharma (USA) LLC
See details and how to join2024-512707-40-00 · EU 2024-512707-40-00 - 3. fázisTaking peopleA clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis
- Where
- Anderlecht, Bonheiden, Leuven, Roeselare
- Életkor
- 18 év and over
- People
- 677 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2025-521546-23-00 · EU 2025-521546-23-00 - No phaseTaking peopleGait Adaptability in Persons With MS Having Mild Disability
- Where
- Diepenbeek
- Életkor
- 18 év to 65 év
- People
- 32
- Run by
- Hasselt University
See details and how to joinNCT07580820 - No phaseTaking peopleCognitive-motor Telerehabilitation in MS
- Where
- Brussels, Melsbroek
- Életkor
- 18 év to 65 év
- People
- 90
- Run by
- Universitair Ziekenhuis Brussel
See details and how to joinNCT05355389 - 2. fázisNot yet taking people in BelgiumA Phase IIa Study of Vitamin D3 Tolerogenic Dendritic Cells (tolDC) for Multiple Sclerosis
- Where
- Edegem
- Életkor
- 18 év to 65 év
- People
- 14 worldwide
- Run by
- University Hospital, Antwerp
See details and how to joinNCT07020715 · EU 2025-522040-40-01 - No phaseTaking peopleMeasurement Properties of the Walking Adaptability Ladder Test and Foot Tap Test in Multiple Sclerosis
- Where
- Diepenbeek
- Életkor
- 18 év to 65 év
- People
- 100 worldwide
- Run by
- Hasselt University
See details and how to joinNCT07505355 - No phaseTaking peoplePrognostic Value of Cerebrospinal Fluid Immunoglobulin Free Light Chains in Patients With Multiple Sclerosis
- Where
- Brussels
- Életkor
- 18 év and over
- People
- 100
- Run by
- Francis Corazza
See details and how to joinNCT05072691 - No phaseTaking peopleA Specialized Diet for Multiple Sclerosis
- Where
- Diepenbeek
- Életkor
- 30 év to 65 év
- People
- 100
- Run by
- Jerome J. A. Hendriks
See details and how to joinNCT07033975 - No phaseNot yet taking people in BelgiumTranscranial Electrical Stimulation in Multiple Sclerosis
- Where
- Brussels, Melsbroek
- Életkor
- 18 év and over
- People
- 100
- Run by
- Universitair Ziekenhuis Brussel
See details and how to joinNCT06966128